SAB Biotherapeutics (SABS) Shares Outstanding (2020 - 2026)

SAB Biotherapeutics' Shares Outstanding (Entity) history runs 5 years deep, the most recent figure standing at $47.7 million for Q4 2025.

• Quarterly Shares Outstanding (Entity) rose 410.13% year-over-year to $47.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $47.7 million (up 410.13% YoY) and the FY2025 annual result came in at $47.7 million, up 410.13% from the prior year.
• Shares Outstanding (Entity) was $47.7 million for Q4 2025 at SAB Biotherapeutics, up from $10.7 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $47.7 million in Q4 2025 and bottomed at $1.5 million in Q3 2021.
• A 5-year average of $8.8 million and a median of $5.4 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Peak annual rise in Shares Outstanding (Entity) reached 410.13% in 2025, while the deepest fall reached 0.67% in 2025.
• SAB Biotherapeutics' Shares Outstanding (Entity) stood at $2.7 million in 2021, then jumped by 86.33% to $5.1 million in 2022, then gained by 8.39% to $5.5 million in 2023, then surged by 69.22% to $9.3 million in 2024, then surged by 410.13% to $47.7 million in 2025.
• Business Quant data shows SABS's Shares Outstanding (Entity) at $47.7 million in Q4 2025, $10.7 million in Q3 2025, and $9.3 million in Q2 2025.